TEANECK, N.J., Oct. 7 /PRNewswire/ -- Eisai Inc. today announces the immediate appointment of Frank Ciriello as Vice President of Sales & Marketing. In his role, Mr. Ciriello will be responsible for the development and execution of marketing and sales strategies to drive the profitable growth of Eisai's full pharmaceutical product line.
Mr. Ciriello joined Eisai from Aventis, where he served in various positions since 1985, prior to the formation of the Aventis organization. His most recent position was Vice President, Respiratory Franchise Head, Global Marketing and Medical.
Mr. Ciriello began his career with Marion Laboratories as a Field Sales Representative in New York City and subsequently held additional field positions as a Hospital Sales Representative and as a District Sales Manager, before moving into product management in 1993. Since then, he has held a number of progressively responsible positions in marketing and management that have spanned numerous therapeutic lines and across the various companies formed from subsequent merger activity.
"Mr. Ciriello brings a wealth of talent and experience in the pharmaceutical industry to Eisai," said Lonnel Coats, President & COO. "As we continue to expand our sales force in support of our leading treatments, Aricept(R) (donepezil hydrochloride tablets), Aciphex(R) (rabeprazole sodium tablets), and Zonegran(R) (zonisamide capsules), we are confident that Mr. Ciriello will play a key role in helping Eisai achieve its sales and growth goals."
About Eisai Inc.
Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care company that discovers, develops, and markets products in more than 30 countries.
Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1.7 billion in fiscal year 2003 (year ending March 31, 2004).
Eisai Inc. employs approximately 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in its CNS, neurology, primary care and hospital field forces. Between 1998 and 2003, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 20.
For full prescribing information on Aricept(R), Aciphex(R) and Zonegran(R), visit http://www.eisai.com/ .